15 March 2018 - - Lyon, France-based biopharmaceutical company Poxel SA (Euronext POXEL - FR0012432516) has commenced the TIMES 2 and TIMES 3 trials for the Phase 3 program for Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, the company said.
Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 program in Japan includes three pivotal trials to evaluate Imeglimin's efficacy and safety in approximately 1,100 patients.
Imeglimin is an orally-available drug candidate with a novel mechanism of action that has been observed in clinical studies to demonstrate glucose lowering benefits by simultaneously targeting all three key organs which play an important role in the treatment of type 2 diabetes: the liver, muscles and the pancreas.
Imeglimin has demonstrated in preclinical studies the potential to address mitochondrial dysfunction, which is believed to be at the core of type 2 diabetes pathophysiology. Imeglimin has completed Phase 1 and Phase 2 development in over 1,200 subjects in the US, EU, and Japan.
Poxel is focused on the development of innovative treatments for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis.